Literature DB >> 12368045

The nature and mechanisms of DN regulatory T-cell mediated suppression.

Kevin J Young1, Li Zhang.   

Abstract

Regulatory T cells have been reported to enhance survival of transplanted allografts. We have recently identified and cloned a novel CD3(+)CD4(-)CD8(-) (double negative, DN) regulatory T cell from mice that were given a single class I mismatched donor lymphocyte infusion and permanently accepted donor-specific skin allografts. When infused into naïve syngeneic mice, these DN T cells prolonged the survival of class I mismatched donor skin allografts. Here we further characterize the nature and mechanism of DN T-cell mediated suppression. This present study reveals that DN T cells are able to specifically eliminate activated syngeneic CD8(+) T cells that share the same T cell receptor (TCR) specificity as DN T cells in vitro. Similarly, we found that, along with an increase of recipient DN T cells in the peripheral blood, anti-donor CD8(+) T cells were also eliminated in vivo following a donor lymphocyte infusion. We further demonstrate that DN T regulatory cells do not mediate suppression by competition for growth factors or antigen presenting cells (APC) nor by modulation of APC, but require cell contact with the activated target CD8(+) T cells. This contact can be mediated either by the TCR on CD8(+) T cells that recognize constitutively expressed or acquired MHC molecules on DN T cells, or by the TCR on DN T cells that recognize constitutively expressed MHC molecules on CD8(+) T cells. Together, these data extend our previous findings, and expand the conditions in which DN T cells can potentially be used to specifically suppress allogeneic immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368045     DOI: 10.1016/s0198-8859(02)00446-9

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

Review 1.  Identification and characterization of CD8+ suppressor T cells.

Authors:  James C Zimring; Judith A Kapp
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions.

Authors:  Stephen C Juvet; Li Zhang
Journal:  J Mol Cell Biol       Date:  2012-02       Impact factor: 6.216

Review 3.  Double-negative regulatory T cells: non-conventional regulators.

Authors:  Christopher W Thomson; Boris P-L Lee; Li Zhang
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Advances on Non-CD4 + Foxp3+ T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation.

Authors:  Ann J Ligocki; Jerry Y Niederkorn
Journal:  Transplantation       Date:  2015-08       Impact factor: 4.939

Review 5.  CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.

Authors:  Zhiheng Wu; Yu Zheng; Jin Sheng; Yicheng Han; Yanyan Yang; Hongming Pan; Junlin Yao
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

Review 6.  Application of double-negative T cells in haematological malignancies: recent progress and future directions.

Authors:  Xingchi Chen; Dongyao Wang; Xiaoyu Zhu
Journal:  Biomark Res       Date:  2022-03-14

Review 7.  Double Negative T Regulatory Cells: An Emerging Paradigm Shift in Reproductive Immune Tolerance?

Authors:  Enitome E Bafor; Julio C Valencia; Howard A Young
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

8.  Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.

Authors:  Erin E Hillhouse; Jean-Sébastien Delisle; Sylvie Lesage
Journal:  Front Immunol       Date:  2013-01-24       Impact factor: 7.561

9.  Identification of CD3+CD4-CD8- T cells as potential regulatory cells in an experimental murine model of graft-versus-host skin disease (GVHD).

Authors:  Fumi Miyagawa; Naoko Okiyama; Vadim Villarroel; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2013-05-06       Impact factor: 8.551

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.